Genor Biopharma Holdings Limited (HK:6998)
:6998
Want to see HK:6998 full AI Analyst Report?
6998 Stock Chart & Stats
HK$3.06
HK$0.04(2.16%)
At close: 4:00 PM EST
HK$3.06
HK$0.04(2.16%)
Day’s Range― - ―
52-Week RangeHK$1.71 - HK$5.60
Previous CloseN/A
Volume193.50K
Average Volume (3M)909.38K
Market Cap
HK$3.51B
Enterprise ValueHK$1.34B
Total Cash (Recent Filing)HK$1.06B
Total Debt (Recent Filing)HK$1.49B
Price to Earnings (P/E)5.1
Beta0.45
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,011,213,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.17
Price to Sales (P/S)1.86
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Profitability TurnaroundThe sharp 2025 swing to significant revenue and positive margins demonstrates the company can scale biologics commercialization and convert R&D into profitable sales. Durable profitability supports reinvestment into pipelines, funds commercialization and reduces reliance on external capital over multiple years.
Positive Cash GenerationMaterial positive operating and free cash flow in 2025 provides internal funding for manufacturing expansion, R&D and potential partnerships. Sustained FCF would lower financing needs and indicate improved earnings quality and cash conversion versus prior loss years.
Strong Capital Base, Moderate LeverageA meaningful equity base with moderate leverage gives financial flexibility to fund clinical programs, capex for large-scale biologics manufacturing, and absorb shocks. This balance sheet profile supports long-term strategic execution and partnership or CDMO opportunities.
Bears Say
Historical Revenue And Profit VolatilityMulti-year instability in revenue and recurring losses through 2020–2024 weakens confidence that 2025’s improvement is durable. This history raises execution risk for commercialization and makes forecasting margins and cash flows across 2–6 months to years less reliable.
Sharp Increase In DebtRapid accumulation of debt elevates interest and refinancing risk, constraining capital flexibility. If revenue or margins revert, debt servicing could crowd out R&D and capex spending and increase vulnerability to adverse funding conditions over the medium term.
Cash Generation Not Proven Through CyclesThe one-year swing to positive FCF may reflect timing or base effects; several prior years of negative cash flow indicate the company must prove consistent cash conversion across cycles to reliably fund operations and growth without external financing.
Genor Biopharma Holdings Limited News
6998 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was HK$1.71 and its highest was HK$5.60 in the past 12 months.
What is Genor Biopharma Holdings Limited’s market cap?
Genor Biopharma Holdings Limited’s market cap is HK$3.51B.
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
Genor Biopharma Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 87 days.
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Genor Biopharma Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.375 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.375.
Is Genor Biopharma Holdings Limited overvalued?
According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued.
Does Genor Biopharma Holdings Limited pay dividends?
Genor Biopharma Holdings Limited does not currently pay dividends.
What is Genor Biopharma Holdings Limited’s EPS estimate?
Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genor Biopharma Holdings Limited have?
Genor Biopharma Holdings Limited has 2,011,213,700 shares outstanding.
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Genor Biopharma Holdings Limited reported an EPS of HK$0.375 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
Currently, no hedge funds are holding shares in HK:6998
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
Zhaoke Ophthalmology Ltd.
―
Immunotech Biopharm Ltd
―